Vulgarone B is a sesquiterpene ketone best known in AromaForge as a major chemistry marker of cotton lavender oil chemotypes, where it can sit alongside artemisia ketone as a composition-defining constituent. Public evidence is strongest for identity, natural occurrence, and older antimicrobial or pesticidal screening rather than for any human clinical use. The safest archive framing is that vulgarone B is a Santolina-linked marker constituent with notable preclinical antifungal, antibacterial, and molluscicidal signals, but with thin constituent-specific safety data.
Chemical identity and composition
PubChem lists vulgarone B as CID 530428 with formula C15H22O and the tricyclic ketone name 2,6,6,11-tetramethyltricyclo[5.4.0.0(2,8)]undec-10-en-9-one. PubChem synonym data supports CAS 64180-68-3 and the alternate name longiverbenone. In the AromaForge archive, the cotton lavender oil record anchors vulgarone B at 22.13% in a 2025 Santolina chamaecyparissus flower-oil profile, making it a major chemotype-defining constituent rather than a trace marker.
Aroma and practical use
- Use the recorded herbal, camphoraceous, green, bitter, herbaceous descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2003 Journal of Chemical Ecology paper identified vulgarone B as the antifungal constituent in the steam-distilled fraction of Artemisia douglasiana.
This is one of the clearest isolated-compound functional papers for vulgarone B and supports antimicrobial positioning better than any wellness-style claim.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2009 Archives of Pharmacal Research abstract reported that vulgarone B and Artemisia iwayomogi oil showed significant inhibitory activity against antibiotic-susceptible and antibiotic-resistant bacteria, with synergism or additive effects when combined with oxacillin against two Staphylococcus aureus strains.
The paper gives vulgarone B a stronger constituent-specific antibacterial signal than many minor oil constituents, but the work is still laboratory-stage.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2004 Pest Management Science paper reported molluscicidal activity of vulgarone B against ram's horn snail (Planorbella trivolvis).
This finding broadens the pesticidal profile of vulgarone B, but it is not a human-use safety or efficacy study.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No constituent-specific IFRA limit, human dermal study, or repeated-dose toxicology paper for isolated vulgarone B was verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
The strongest accessible literature on vulgarone B concerns antimicrobial and pesticidal screening, so archive copy should avoid implying validated medical or wellness effects in people.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
The parent Santolina oil has a publicly surfaced fragrance-use prohibition in trade safety summaries, but that oil-level restriction should not be treated as an isolated-compound limit for vulgarone B itself.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
membrane_and_dna_disruption_hypothesis
The accessible antibacterial abstract preview links vulgarone B activity to observed bacterial morphology changes and DNA effects, but this remains a preclinical mechanism signal rather than a validated human-use pathway.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- No human clinical literature specific to isolated vulgarone B was verified in this pass.
- No constituent-specific dermal sensitization, inhalation tolerance, or chronic toxicology source was located in the reviewed public literature.
- Most functional evidence is older antimicrobial or pesticidal work rather than modern mechanistic or translational human-use research.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.